uftoral has been researched along with Bile Duct Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hirano, T; Kitahara, K; Magata, S; Matsuyama, S; Miyazaki, K; Mori, M; Shimonishi, T | 1 |
Hioki, M; Hirano, S; Hirata, T; Hisayoshi, T; Kutsukata, N; Masuda, S; Yamagishi, S; Yamamoto, S; Yamashita, Y | 1 |
2 other study(ies) available for uftoral and Bile Duct Cancer
Article | Year |
---|---|
[A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Common Bile Duct; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Radiotherapy, High-Energy; Remission Induction; Tegafur; Uracil | 2004 |
[A case of far-advanced gastric cancer treated with neoadjuvant combination chemotherapy of UFT, low-dose CDDP and leucovorin, followed by subtotal gastrectomy with curative intent].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Leucovorin; Male; Neoplasm Invasiveness; Portal Vein; Stomach Neoplasms; Tegafur; Uracil | 1997 |